Invex Therapeutics Financials
| IXC Stock | 0.07 0 4.29% |
Operating Margin 0.2934 | Profit Margin (1.35) | Return On Equity (0.12) |
Invex | Select Account or Indicator |
Understanding current and past Invex Therapeutics Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Invex Therapeutics' financial statements are interrelated, with each one affecting the others. For example, an increase in Invex Therapeutics' assets may result in an increase in income on the income statement.
Please note, the imprecision that can be found in Invex Therapeutics' accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Invex Therapeutics. Check Invex Therapeutics' Beneish M Score to see the likelihood of Invex Therapeutics' management manipulating its earnings.
Invex Therapeutics Stock Summary
Invex Therapeutics competes with FSA, Tamawood, Cochlear, Rea, and Macquarie. Invex Therapeutics is entity of Australia. It is traded as Stock on AU exchange.| Foreign Associate | USA |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Instrument | Australia Stock View All |
| Exchange | Australian Securities Exchange |
| ISIN | AU0000048621 |
| Business Address | 38 Rowland Street, |
| Sector | Biotechnology |
| Industry | Health Care |
| Benchmark | Dow Jones Industrial |
| Website | www.invextherapeutics.com |
| Phone | 61 8 6382 0137 |
You should never invest in Invex Therapeutics without having analyzed its financial statements. Do not rely on someone else's analysis or guesses about the future performance of Invex Stock, because this is throwing your money away. Analyzing the key information contained in Invex Therapeutics' financial statements can give you an edge over other investors and help to ensure that your investments perform well for you.
Invex Therapeutics Key Financial Ratios
Invex Therapeutics' financial ratios allow both analysts and investors to convert raw data from Invex Therapeutics' financial statements into concise, actionable information that can be used to evaluate the performance of Invex Therapeutics over time and compare it to other companies across industries.| Revenue | 1.21 M | ||||
| Gross Profit | 459.08 K | ||||
| EBITDA | (720.44 K) | ||||
| Net Income | (1.64 M) | ||||
| Total Asset | 6.12 M |
Invex Therapeutics Key Balance Sheet Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Total Assets | 26.4M | 32.7M | 29.5M | 22.8M | 6.1M | 5.8M | |
| Net Debt | (26.3M) | (32.7M) | (29.3M) | (22.5M) | (6.0M) | (6.3M) | |
| Retained Earnings | (3.6M) | (5.9M) | (9.8M) | (17.6M) | (19.2M) | (18.3M) | |
| Accounts Payable | 30.4K | 11.3K | 138.8K | 1.1M | 5.6K | 5.3K | |
| Cash | 26.3M | 32.7M | 29.3M | 22.5M | 6.0M | 5.7M | |
| Net Receivables | 116.9K | 21.2K | 145.7K | 333.6K | 95.0K | 146.3K | |
| Inventory | (116.9K) | (21.2K) | (145.7K) | (333.6K) | (95.0K) | (99.7K) | |
| Other Current Assets | 116.9K | 21.2K | 145.7K | 333.6K | 95.0K | 146.3K | |
| Total Liab | 2.0M | 658.6K | 1.0M | 1.6M | 431.6K | 410.0K | |
| Total Current Assets | 26.4M | 32.7M | 29.5M | 22.8M | 6.1M | 5.8M |
Invex Therapeutics Key Income Statement Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Total Revenue | 165.7K | 158.8K | 182.3K | 459.1K | 1.2M | 1.3M | |
| Operating Income | (3.3M) | (2.4M) | (4.0M) | (8.5M) | (2.1M) | (2.2M) | |
| Ebit | (3.3M) | (4.9M) | (8.3M) | (17.5M) | (2.9M) | (3.0M) | |
| Research Development | 1.6M | 1.1M | 3.0M | 7.4M | 2.0M | 2.8M | |
| Ebitda | (3.3M) | (2.4M) | (4.2M) | (9.0M) | (720.4K) | (756.5K) | |
| Income Before Tax | (3.4M) | (2.3M) | (4.0M) | (7.7M) | (2.9M) | (3.0M) | |
| Net Income | (3.4M) | (2.3M) | (4.0M) | (7.7M) | (1.6M) | (1.7M) | |
| Income Tax Expense | (47.8K) | (2.4M) | (4.1M) | (9.3M) | (1.2M) | (1.3M) |
Invex Therapeutics Key Cash Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Change In Cash | 14.1M | 6.4M | (3.4M) | (6.9M) | (16.4M) | (15.6M) | |
| Free Cash Flow | (1.6M) | (1.7M) | (3.4M) | (6.9M) | (2.4M) | (2.6M) | |
| Change In Working Capital | 661.5K | 95.7K | (124.5K) | (187.9K) | (902.2K) | (857.1K) | |
| Begin Period Cash Flow | 12.2M | 26.3M | 32.7M | 29.3M | 22.5M | 18.1M | |
| Other Non Cash Items | 112.0K | (52.7K) | 348.6K | 588.0K | (802.2K) | (762.1K) | |
| Total Cash From Operating Activities | (1.6M) | (1.7M) | (3.4M) | (6.9M) | (2.4M) | (2.6M) | |
| Change To Account Receivables | 36.5K | 95.7K | (124.5K) | (187.9K) | 238.6K | 250.5K | |
| Net Income | (3.4M) | (2.3M) | (4.0M) | (7.7M) | (1.6M) | (1.7M) | |
| End Period Cash Flow | 26.3M | 32.7M | 29.3M | 22.5M | 6.0M | 5.7M |
Invex Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Invex Therapeutics's current stock value. Our valuation model uses many indicators to compare Invex Therapeutics value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Invex Therapeutics competition to find correlations between indicators driving Invex Therapeutics's intrinsic value. More Info.Invex Therapeutics is rated third overall in return on equity category among its peers. It also is rated third overall in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Invex Therapeutics' earnings, one of the primary drivers of an investment's value.Invex Therapeutics Systematic Risk
Invex Therapeutics' systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Invex Therapeutics volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was twenty-eight with a total number of output elements of thirty-three. The Beta measures systematic risk based on how returns on Invex Therapeutics correlated with the market. If Beta is less than 0 Invex Therapeutics generally moves in the opposite direction as compared to the market. If Invex Therapeutics Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Invex Therapeutics is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Invex Therapeutics is generally in the same direction as the market. If Beta > 1 Invex Therapeutics moves generally in the same direction as, but more than the movement of the benchmark.
Invex Therapeutics Total Assets Over Time
Invex Therapeutics December 3, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Invex Therapeutics help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Invex Therapeutics. We use our internally-developed statistical techniques to arrive at the intrinsic value of Invex Therapeutics based on widely used predictive technical indicators. In general, we focus on analyzing Invex Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Invex Therapeutics's daily price indicators and compare them against related drivers.
| Information Ratio | (0.04) | |||
| Maximum Drawdown | 27.99 | |||
| Value At Risk | (5.00) | |||
| Potential Upside | 4.17 |
Additional Tools for Invex Stock Analysis
When running Invex Therapeutics' price analysis, check to measure Invex Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Invex Therapeutics is operating at the current time. Most of Invex Therapeutics' value examination focuses on studying past and present price action to predict the probability of Invex Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Invex Therapeutics' price. Additionally, you may evaluate how the addition of Invex Therapeutics to your portfolios can decrease your overall portfolio volatility.